Dihexa Research: What 18 Studies Show (2026) | RetatrutideCompare

Dihexa — 18 studies indexed on PubMed. Hepatocyte growth factor (HGF) / c-Met receptor agonist that promotes synaptogenesis and dendritic spine density in hippocampal neurons. Half-life: Hours (oral, BBB penetrant). FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Dihexa?

There are approximately 18 studies indexed on PubMed that mention Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), based on a search last updated 2026-06-18.

Is Dihexa FDA-approved?

FDA status: Not FDA-approved.

How does Dihexa work?

Hepatocyte growth factor (HGF) / c-Met receptor agonist that promotes synaptogenesis and dendritic spine density in hippocampal neurons.

Hepatocyte growth factor (HGF) / c-Met receptor agonist that promotes synaptogenesis and dendritic spine density in hippocampal neurons.

Reference facts

Also known as
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Category
Nootropic & Cognitive
Mechanism of action
Hepatocyte growth factor (HGF) / c-Met receptor agonist that promotes synaptogenesis and dendritic spine density in hippocampal neurons.
Targets
HGF / c-Met signaling
Indications under research or approved
Research — Alzheimer's, cognitive enhancement
Regulatory status (reference entry)
Not FDA-approved
Half-life
Hours (oral, BBB penetrant)
Sequence notes
Modified angiotensin IV mimetic with non-natural N-hexanoyl and aminohexanoic acid groups for oral bioavailability.
Molecular weight (Da)
433
Originator / sponsor
Originally M3 Biotechnology
First reported
2012

Primary References

Explore research articles about Dihexa

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.